Published in J Immune Based Ther Vaccines on June 26, 2011
Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat Med (1996) 5.38
An antimicrobial activity of cytolytic T cells mediated by granulysin. Science (1998) 5.02
Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science (1998) 4.58
Vaccination against tuberculosis by DNA injection. Nat Med (1996) 3.76
Cytokine secretion by CD4 T lymphocytes acquired in response to Mycobacterium tuberculosis infection. J Immunol (1993) 3.51
Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci U S A (2000) 3.07
Therapy of tuberculosis in mice by DNA vaccination. Nature (1999) 2.99
Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis. Am J Respir Crit Care Med (2003) 2.59
Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis. Infect Immun (1999) 2.57
T-cell cytokine responses in human infection with Mycobacterium tuberculosis. Infect Immun (1995) 2.57
Human T-cell responses to secreted antigen fractions of Mycobacterium tuberculosis. Infect Immun (1995) 2.39
Tuberculosis vaccine development: recent progress. Trends Microbiol (2001) 2.15
Multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis: epidemiology and control. Expert Rev Anti Infect Ther (2007) 2.06
Long term efficacy of DOTS regimens for tuberculosis: systematic review. BMJ (2008) 1.85
Immunogenicity and efficacy of a tuberculosis DNA vaccine encoding the components of the secreted antigen 85 complex. Vaccine (1997) 1.83
Protective effect of DNA vaccine during chemotherapy on reactivation and reinfection of Mycobacterium tuberculosis. Gene Ther (2005) 1.66
Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model. Infect Immun (2004) 1.65
Identification and characterization of protective T cells in hsp65 DNA-vaccinated and Mycobacterium tuberculosis-infected mice. Infect Immun (1998) 1.64
Protection against tuberculosis by a plasmid DNA vaccine. Vaccine (1997) 1.48
Quantitative bacillary response to treatment in HIV-associated pulmonary tuberculosis. Am Rev Respir Dis (1993) 1.47
Effective preexposure tuberculosis vaccines fail to protect when they are given in an immunotherapeutic mode. Infect Immun (2000) 1.36
Passive serum therapy with polyclonal antibodies against Mycobacterium tuberculosis protects against post-chemotherapy relapse of tuberculosis infection in SCID mice. Microbes Infect (2006) 1.16
Immunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis. Vaccine (2005) 1.15
Therapeutic effect of DNA vaccines combined with chemotherapy in a latent infection model after aerosol infection of mice with Mycobacterium tuberculosis. Gene Ther (2003) 1.14
Immunotherapy with plasmid DNA encoding mycobacterial hsp65 in association with chemotherapy is a more rapid and efficient form of treatment for tuberculosis in mice. Gene Ther (2005) 1.05
Immune response to recombinant mycobacterial proteins in patients with tuberculosis infection and disease. J Infect Dis (1996) 1.05
DNA immunization in a mouse model of latent tuberculosis: effect of DNA vaccination on reactivation of disease and on reinfection with a secondary challenge. Infect Immun (2002) 0.98
Expanding the antigenic repertoire of BCG improves protective efficacy against aerosol Mycobacterium tuberculosis infection. Vaccine (2005) 0.97
Expression and immunogenicity of Mycobacterium tuberculosis antigen 85 by DNA vaccination. Vaccine (1997) 0.97
Comparative analysis of different vaccine constructs expressing defined antigens from Mycobacterium tuberculosis. J Infect Dis (2004) 0.95
A multivalent combination of experimental antituberculosis DNA vaccines based on Ag85B and regions of difference antigens. Microbes Infect (2006) 0.94
Current strategies in TB immunotherapy. Curr Mol Med (2007) 0.90
Efficient tuberculosis treatment in mice using chemotherapy and immunotherapy with the combined DNA vaccine encoding Ag85B, MPT-64 and MPT-83. Gene Ther (2008) 0.90
Adjunct immunotherapy with Ag85 complex proteins based subunit vaccine in a murine model of Mycobacterium tuberculosis infection. Immunotherapy (2009) 0.78
Genetic screening reveals high frequency of PARK2 mutations and reduced Parkin expression conferring risk for Parkinsonism in North West India. J Neurol Neurosurg Psychiatry (2009) 1.48
Diagnosis of extrapulmonary tuberculosis by PCR. FEMS Immunol Med Microbiol (2012) 1.20
Potential role for ESAT6 in dissemination of M. tuberculosis via human lung epithelial cells. Mol Microbiol (2009) 1.09
The potential of azole antifungals against latent/persistent tuberculosis. FEMS Microbiol Lett (2006) 1.05
Nanobead-based interventions for the treatment and prevention of tuberculosis. Nat Rev Microbiol (2010) 0.99
Poly(lactide-co-glycolide)-rifampicin nanoparticles efficiently clear Mycobacterium bovis BCG infection in macrophages and remain membrane-bound in phago-lysosomes. J Cell Sci (2013) 0.98
Tuberculosis subunit vaccine design: the conflict of antigenicity and immunogenicity. Clin Immunol (2007) 0.95
IFN-γ (+874) and not TNF-α (-308) is associated with HBV-HCC risk in India. Mol Cell Biochem (2013) 0.95
A multivalent combination of experimental antituberculosis DNA vaccines based on Ag85B and regions of difference antigens. Microbes Infect (2006) 0.94
Role of human neutrophil peptide-1 as a possible adjunct to antituberculosis chemotherapy. J Infect Dis (2004) 0.93
Comparative evaluation of intranasal and subcutaneous route of immunization for development of mucosal vaccine against experimental tuberculosis. FEMS Immunol Med Microbiol (2005) 0.93
In vitro and in vivo synergistic effects of cryptdin 2 and ampicillin against Salmonella. Antimicrob Agents Chemother (2011) 0.92
Enhanced immunoprotective potential of Mycobacterium tuberculosis Ag85 complex protein based vaccine against airway Mycobacterium tuberculosis challenge following intranasal administration. FEMS Immunol Med Microbiol (2006) 0.92
The Sarcoid-Tuberculosis link: evidence from a high TB prevalence country. J Infect (2010) 0.91
Expression and purification of the Mycobacterium tuberculosis complex-restricted antigen CFP21 to study its immunoprophylactic potential in mouse model. Protein Expr Purif (2006) 0.90
Cryptdin-2: a novel therapeutic agent for experimental Salmonella Typhimurium infection. J Antimicrob Chemother (2010) 0.90
Peripheral blood and pleural fluid mononuclear cell responses to low-molecular-mass secretory polypeptides of Mycobacterium tuberculosis in human models of immunity to tuberculosis. Infect Immun (2005) 0.90
Utility of a combination of RD1 and RD2 antigens as a diagnostic marker for tuberculosis. Diagn Microbiol Infect Dis (2009) 0.88
Multicomponent antituberculous subunit vaccine based on immunodominant antigens of Mycobacterium tuberculosis. Vaccine (2005) 0.88
Chemotherapeutic evaluation of alginate nanoparticle-encapsulated azole antifungal and antitubercular drugs against murine tuberculosis. Nanomedicine (2007) 0.87
Immunodominance of low molecular weight secretory polypeptides of Mycobacterium tuberculosis to induce cytotoxic T-lymphocyte response. Vaccine (2005) 0.87
Supplementation with RD antigens enhances the protective efficacy of BCG in tuberculous mice. Clin Immunol (2007) 0.86
Interleukin-1 polymorphism and expression in hepatitis B virus-mediated disease outcome in India. J Interferon Cytokine Res (2012) 0.86
Protective efficacy of intranasal vaccination with Mycobacterium bovis BCG against airway Mycobacterium tuberculosis challenge in mice. J Infect (2006) 0.85
Nanoparticle-based oral drug delivery system for an injectable antibiotic - streptomycin. Evaluation in a murine tuberculosis model. Chemotherapy (2007) 0.85
Immune responses to mycobacterial antigens in sarcoidosis: a systematic review. Indian J Chest Dis Allied Sci (2011) 0.85
Pharmacokinetic and pharmacodynamic behaviour of antitubercular drugs encapsulated in alginate nanoparticles at two doses. Int J Antimicrob Agents (2006) 0.84
Effect of IL-12B, IL-2, TGF-β1, and IL-4 polymorphism and expression on hepatitis B progression. J Interferon Cytokine Res (2013) 0.84
Peptide deformylase--a promising therapeutic target for tuberculosis and antibacterial drug discovery. Expert Opin Ther Targets (2009) 0.83
Is intranasal vaccination a feasible solution for tuberculosis? Expert Rev Vaccines (2008) 0.83
Detection of potential microbial antigens by immuno-PCR (PCR-amplified immunoassay). J Med Microbiol (2014) 0.82
Utility of adenosine deaminase (ADA), PCR & thoracoscopy in differentiating tuberculous & non-tuberculous pleural effusion complicating chronic kidney disease. Indian J Med Res (2015) 0.82
Association of interleukin-10 with hepatitis B virus (HBV) mediated disease progression in Indian population. Indian J Med Res (2014) 0.82
IL-6(-572/-597) polymorphism and expression in HBV disease chronicity in an Indian population. Am J Hum Biol (2014) 0.81
Identification of Mycobacterium avium KatG protein (MAV_2753) as a possible serodiagnostic marker for MAC disease. J Infect (2009) 0.81
Analysis of humoral responses to proteins encoded by region of difference 1 of Mycobacterium tuberculosis in sarcoidosis in a high tuberculosis prevalence country. Indian J Med Res (2012) 0.81
Immunomodulation of alveolar epithelial cells by Mycobacterium tuberculosis phosphatidylinositol mannosides results in apoptosis. APMIS (2013) 0.80
Development of an ultrasensitive polymerase chain reaction-amplified immunoassay based on mycobacterial RD antigens: implications for the serodiagnosis of tuberculosis. Diagn Microbiol Infect Dis (2012) 0.80
Effect of mycobacterial secretory proteins on the cellular integrity and cytokine profile of type II alveolar epithelial cells. Lung India (2012) 0.79
Adjunct immunotherapy with Ag85 complex proteins based subunit vaccine in a murine model of Mycobacterium tuberculosis infection. Immunotherapy (2009) 0.78
Evaluation of Mycobacterium tuberculosis specific RD antigens for delayed type hypersensitivity responses in guinea pig. Indian J Exp Biol (2010) 0.78
Interaction of alveolar epithelial cells with CFP21, a mycobacterial cutinase-like enzyme. Mol Cell Biochem (2014) 0.77
Identification and purification of CREB like protein in Candida albicans. Mol Cell Biochem (2007) 0.77
cAMP regulates vegetative growth and cell cycle in Candida albicans. Mol Cell Biochem (2007) 0.77
Homocysteine--risk factor for ischemic stroke? Indian J Physiol Pharmacol (2009) 0.76
Evaluation of Aro-Tal-AST Complex Protein as a Marker for Differential Diagnosis of Mycobacterium Avium Infection. J Glob Infect Dis (2011) 0.75
Nonspecificity of 35 kDa protein: a proposed marker for the differential diagnosis of M. avium infection in the Indian population. Indian J Pathol Microbiol (2010) 0.75